The exclusive rights to commercialization rights to SRP-9001, the United States based pharma biotech company Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD), will be bought by Basel, Switzerland-based Roche in a $1.15 billion deal. The deal will allow Roche to launch...